hVIVO and Imutex to present at IVW 2019

hVIVO plc

("hVIVO" or the "Company")

hVIVO and Imutex Limited to present at the Influenza Vaccines for the World (IVW 2019) conference at the Royal College of Physicians of Edinburgh, Scotland

London, UK 29 March 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, confirms that the Company and its joint venture, Imutex Limited, will present at the Influenza Vaccines for the World (IVW 2019) conference on 2-4 April 2019 at the Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK.

IVW 2019 is an international conference and exhibition in an important series of influenza vaccine meetings focused on 'Influenza Vaccination Issues'. The IVW series is an international forum for world renowned experts in the field of influenza vaccines and related issues (adjuvants / delivery / vaccination strategies) to report on the latest data and trends associated with current and new influenza vaccines / technologies and their availability / delivery / implementation worldwide.

Presentation details are as follows:

Title: FLU-v, a broad spectrum influenza vaccine: cross-reactivity and field results

Presenter: Dr Olga Pleguezuelos, Imutex (SEEK)

Date and time: Tuesday, 2 April 2019, Session 3,12.10-12.40

Location: Royal College of Physicians of Edinburgh, Scotland, UK

Title: The future for FLU-v: Efficacy results from an H1N1 challenge study

Presenter: Dr Emma James, Imutex (SEEK)

Date and time: Tuesday, 2 April 2019, Session 4, 14.30-15.00

Location: Royal College of Physicians of Edinburgh, Scotland, UK

Title: The human viral challenge and the evaluation of novel/universal vaccines

Presenter: Dr Rob Lambkin-Williams, hVIVO

Date and time: Wednesday, 3 April 2019, Session 6, 09.30-09:50

Location: Royal College of Physicians of Edinburgh, Scotland, UK

For further information please contact:

About FLU-v - a Phase III enabled, broad spectrum stand-alone, universal influenza vaccine candidate:

FLU-v is a novel first-in-class, broad spectrum, true stand-alone, influenza vaccine candidate. FLU-v is designed to provide broad spectrum cover against multiple influenza strains and does not require annual immunisation alongside an annual influenza vaccine to confer immunity. It is also designed to minimise the impact of the influenza virus by reducing symptoms, potentially relegating influenza to a much milder disease by stimulating an immune response mediated through T-cells and B-cells to the internal proteins, in contrast to seasonal influenza vaccines that prevent infection through antibody protection against external proteins. In 2017, there were two FLU-v Phase IIb studies conducted- 003 (field study) and 004 (human viral challenge study).

FLU-v is a synthetic polypeptide vaccine which means that it is not reliant on traditional manufacturing techniques with inherent risks, in particular the potential of a mismatch of virus particularly relevant for a pandemic strain. FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain.

FLU-v is being developed by Imutex Limited, hVIVO's 49% joint venture with PepTcell Limited, trading as the SEEK Group ("SEEK").

About hVIVO:

hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.

About SEEK Group (PepTCell Limited, trading as SEEK Group):

SEEK's strategy is to bring safe, effective and low-cost medicines to patients as quickly as possible, to radically improve human health in major disease areas.

We do this by:

· Modifying existing medicines to improve their efficacy

· Using existing medicines in new indications

· Creating new chemical entities

Working in these different ways allows us to optimise the regulatory approval pathway to ensure that we bring safe and effective products to patients in the shortest possible time.